Search

Your search keyword '"Tuffy, Kevin M."' showing total 23 results

Search Constraints

Start Over You searched for: Author "Tuffy, Kevin M." Remove constraint Author: "Tuffy, Kevin M."
23 results on '"Tuffy, Kevin M."'

Search Results

1. Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

2. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

3. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

4. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

5. Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitroIC50 values predict SARS‐CoV‐2 neutralising antibody titres.

8. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

9. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants

10. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

11. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

12. 94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants

13. 1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies

14. Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

15. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

17. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).

18. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

21. Cytoskeleton-Associated Protein 4: Functions Beyond the Endoplasmic Reticulum in Physiology and Disease

23. Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitro IC 50 values predict SARS-CoV-2 neutralising antibody titres.

Catalog

Books, media, physical & digital resources